newsfilter
← Latest News
Business Wire·

Fibrocell Science and Intrexon Expand Collaboration for Potential New Class of Therapeutics

EXTON, Pa. & GERMANTOWN, Md.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, and Intrexon Corporation, a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) for development of a potentially new class of therapeutics.